NeuroRX says that the data submitted to the FDA is consistent with previously released topline data. But the data they released is based on manipulation of the data. We'll see if it slips through the cracks like remdesivir.

Quote:

---

According to NeuroRx, across all patients and sites, RLF-100(TM) met the primary endpoint for successful recovery from respiratory failure at days 28 (P = .014) and 60 (P = .013) and also demonstrated a meaningful benefit in survival (P = < .001) after controlling for ventilation status and treatment site .

---

https://finance.yahoo.com/news/relief-confirm...00337.html